Literature DB >> 26724941

hIgD promotes human Burkitt lymphoma Daudi cell proliferation by accelerated G1/S transition via IgD receptor activity.

Xing Dai1, YuJing Wu1, XiaoYi Jia1, Yan Chang1, HuaXun Wu1, Chun Wang1, HengShi Chen1, WenSheng Chen1, Qiong Huang1, Wei Wei2.   

Abstract

The aim of the present study was to investigate the role and molecular mechanism of human IgD (hIgD) on the proliferation of human Burkitt lymphoma Daudi cells in vitro. Logarithmically growing Daudi cells were treated with hIgD for different time periods, and cell proliferation was evaluated by cell counting kit-8 (CCK-8) assay. The expressions of Daudi surface markers and IgD receptor (IgDR) as well as cell cycle and apoptosis were measured by flow cytometry analysis. Our results showed that hIgD stimulation induced proliferation and IgDR expression and reduced the apoptosis of Daudi cells. Treatment with hIgD promoted progression of the cell cycle at the G1/S transition, and this was accompanied by upregulation of c-myc, cyclin D3, and CDK6 as well as downregulation of p16 mRNA and protein levels. Moreover, hIgD treatment also upregulated the expression of tyrosine phosphorylation of 70 kDa protein (IgDR) and p-Lyn. Taken together, these results indicate that hIgD can induce Daudi cell proliferation through activating IgDR to initiate the tyrosine phosphorylation signaling cascade to accelerate the G1/S transition.

Entities:  

Keywords:  Burkitt lymphoma; G1/S checkpoint; IgD receptor; Proliferation; Tyrosine phosphorylation

Mesh:

Substances:

Year:  2016        PMID: 26724941     DOI: 10.1007/s12026-015-8777-3

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  42 in total

1.  Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells.

Authors:  M Sánchez-Beato; F I Camacho; J C Martínez-Montero; A I Sáez; R Villuendas; L Sánchez-Verde; J F García; M A Piris
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

2.  Biotinylation and analysis of membrane-bound and soluble proteins.

Authors:  M P Lisanti; M Sargiacomo
Journal:  Curr Protoc Immunol       Date:  2001-05

3.  Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.

Authors:  G B Carey; D W Scott
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

4.  IgD-receptor-positive human T lymphocytes. I. Modulation of receptor expression by oligomeric IgD and lymphokines.

Authors:  R F Coico; S L Tamma; M Bessler; C F Wei; G J Thorbecke
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

5.  Cyclin D3 expression in normal, reactive and neoplastic tissues.

Authors:  C Doglioni; C Chiarelli; E Macrí; A P Dei Tos; E Meggiolaro; P Dalla Palma; M Barbareschi
Journal:  J Pathol       Date:  1998-06       Impact factor: 7.996

6.  High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

Authors:  Albert Oriol; Josep-Maria Ribera; Juan Bergua; Eduardo Giménez Mesa; Carlos Grande; Jordi Esteve; Salut Brunet; Maria-Jose Moreno; Lourdes Escoda; Jesus-Maria Hernandez-Rivas; Dieter Hoelzer
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

7.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

8.  Serum immunoglobulin levels in childhood Hodgkin's disease. Effect of splenectomy and long-term follow-up.

Authors:  P D Walzer; D Armstrong; P Weisman; C Tan
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

9.  c-Myc regulates cell proliferation during lens development.

Authors:  Gabriel R Cavalheiro; Gabriel E Matos-Rodrigues; Anielle L Gomes; Paulo M G Rodrigues; Rodrigo A P Martins
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 10.  The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey.

Authors:  Giuseppe Pannone; Rosanna Zamparese; Mirella Pace; Maria Carmela Pedicillo; Simona Cagiano; Pasquale Somma; Maria Elena Errico; Vittoria Donofrio; Renato Franco; Annarosaria De Chiara; Gabriella Aquino; Paolo Bucci; Eduardo Bucci; Angela Santoro; Pantaleo Bufo
Journal:  Infect Agent Cancer       Date:  2014-10-15       Impact factor: 2.965

View more
  3 in total

1.  The immunoglobulin D Fc receptor expressed on fibroblast-like synoviocytes from patients with rheumatoid arthritis contributes to the cell activation.

Authors:  Yu-Jing Wu; Wen-Sheng Chen; Heng-Shi Chen; Xing Dai; Jin Dong; Ying Wang; Ling-Ling Zhang; Yan Chang; Qiong Huang; Xiao-Yi Jia; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  The Elevated Secreted Immunoglobulin D Enhanced the Activation of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis.

Authors:  Yujing Wu; Wensheng Chen; Hengshi Chen; Lingling Zhang; Yan Chang; Shangxue Yan; Xing Dai; Yang Ma; Qiong Huang; Wei Wei
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

3.  CP-25 Attenuates the Activation of CD4+ T Cells Stimulated with Immunoglobulin D in Human.

Authors:  Yu-Jing Wu; Heng-Shi Chen; Wen-Sheng Chen; Jin Dong; Xiao-Jie Dong; Xing Dai; Qiong Huang; Wei Wei
Journal:  Front Pharmacol       Date:  2018-01-23       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.